Galaxy Diagnostics

Better answers for tick-borne disease patients and providers starts with better diagnostics.

We’re proud to announce a strategic investment from Bay Area Lyme Ventures, the newly launched impact investment fund created by Area Lyme Foundation to accelerate innovation in Lyme and tick-borne disease diagnostics and therapeutics.

This investment reflects our shared belief that patients and providers deserve better answers.

For too long, individuals with complex tick and vector-borne illnesses have faced uncertainty, delayed diagnoses, and limited testing options. Together, we’re working to change that.

At Galaxy Diagnostics, our mission has always been to advance diagnostic tools that help clinicians detect these stealth pathogens with greater precision and confidence. This partnership will help accelerate that work and support the continued development of innovative testing technologies for Lyme disease and associated infections.

We’re honored to have the support of an organization that has helped fund so much of the foundational research driving progress in the field today.

Thank you to Bay Area Lyme Ventures for your partnership and commitment to improving outcomes for patients affected by tick-borne disease.

Read the full announcement here: https://www.globenewswire.com/news-release/2026/06/02/3305158/0/en/bay-area-lyme-ventures-invests-in-galaxy-diagnostics-to-advance-tick-borne-disease-testing.html